FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207051048> ?p ?o ?g. }

• W4207051048 endingPage "331" @default.
• W4207051048 startingPage "331" @default.
• W4207051048 abstract "Vaccination against COVID-19 provides clear public health benefits, but vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID-19 vaccination are unclear.To describe reports of myocarditis and the reporting rates after mRNA-based COVID-19 vaccination in the US.Descriptive study of reports of myocarditis to the Vaccine Adverse Event Reporting System (VAERS) that occurred after mRNA-based COVID-19 vaccine administration between December 2020 and August 2021 in 192 405 448 individuals older than 12 years of age in the US; data were processed by VAERS as of September 30, 2021.Vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna).Reports of myocarditis to VAERS were adjudicated and summarized for all age groups. Crude reporting rates were calculated across age and sex strata. Expected rates of myocarditis by age and sex were calculated using 2017-2019 claims data. For persons younger than 30 years of age, medical record reviews and clinician interviews were conducted to describe clinical presentation, diagnostic test results, treatment, and early outcomes.Among 192 405 448 persons receiving a total of 354 100 845 mRNA-based COVID-19 vaccines during the study period, there were 1991 reports of myocarditis to VAERS and 1626 of these reports met the case definition of myocarditis. Of those with myocarditis, the median age was 21 years (IQR, 16-31 years) and the median time to symptom onset was 2 days (IQR, 1-3 days). Males comprised 82% of the myocarditis cases for whom sex was reported. The crude reporting rates for cases of myocarditis within 7 days after COVID-19 vaccination exceeded the expected rates of myocarditis across multiple age and sex strata. The rates of myocarditis were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively). There were 826 cases of myocarditis among those younger than 30 years of age who had detailed clinical information available; of these cases, 792 of 809 (98%) had elevated troponin levels, 569 of 794 (72%) had abnormal electrocardiogram results, and 223 of 312 (72%) had abnormal cardiac magnetic resonance imaging results. Approximately 96% of persons (784/813) were hospitalized and 87% (577/661) of these had resolution of presenting symptoms by hospital discharge. The most common treatment was nonsteroidal anti-inflammatory drugs (589/676; 87%).Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men. This risk should be considered in the context of the benefits of COVID-19 vaccination." @default.
• W4207051048 created "2022-01-26" @default.
• W4207051048 creator A5000498350 @default.
• W4207051048 creator A5005111256 @default.
• W4207051048 creator A5008298552 @default.
• W4207051048 creator A5014457694 @default.
• W4207051048 creator A5025817529 @default.
• W4207051048 creator A5033443383 @default.
• W4207051048 creator A5037780478 @default.
• W4207051048 creator A5040342415 @default.
• W4207051048 creator A5043667545 @default.
• W4207051048 creator A5045016557 @default.
• W4207051048 creator A5045519730 @default.
• W4207051048 creator A5046057748 @default.
• W4207051048 creator A5048412798 @default.
• W4207051048 creator A5051327428 @default.
• W4207051048 creator A5053157450 @default.
• W4207051048 creator A5053435953 @default.
• W4207051048 creator A5059550323 @default.
• W4207051048 creator A5067237537 @default.
• W4207051048 creator A5067425596 @default.
• W4207051048 creator A5068508825 @default.
• W4207051048 creator A5075918695 @default.
• W4207051048 creator A5077130040 @default.
• W4207051048 creator A5077383038 @default.
• W4207051048 creator A5081139573 @default.
• W4207051048 creator A5081321979 @default.
• W4207051048 creator A5085261368 @default.
• W4207051048 date "2022-01-25" @default.
• W4207051048 modified "2023-10-17" @default.
• W4207051048 title "Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021" @default.
• W4207051048 cites W1983466715 @default.
• W4207051048 cites W2008957002 @default.
• W4207051048 cites W2064828900 @default.
• W4207051048 cites W2114852023 @default.
• W4207051048 cites W2119169318 @default.
• W4207051048 cites W2119340816 @default.
• W4207051048 cites W2140921081 @default.
• W4207051048 cites W2154671194 @default.
• W4207051048 cites W2176946150 @default.
• W4207051048 cites W2273527755 @default.
• W4207051048 cites W2313269561 @default.
• W4207051048 cites W2769151024 @default.
• W4207051048 cites W2903759577 @default.
• W4207051048 cites W2944434778 @default.
• W4207051048 cites W2969485631 @default.
• W4207051048 cites W2988186555 @default.
• W4207051048 cites W3138582961 @default.
• W4207051048 cites W3160661236 @default.
• W4207051048 cites W3165142255 @default.
• W4207051048 cites W3166407960 @default.
• W4207051048 cites W3169253227 @default.
• W4207051048 cites W3171107123 @default.
• W4207051048 cites W3176051599 @default.
• W4207051048 cites W3177443097 @default.
• W4207051048 cites W3178327314 @default.
• W4207051048 cites W3178977348 @default.
• W4207051048 cites W3189406732 @default.
• W4207051048 cites W3197576044 @default.
• W4207051048 cites W4226178606 @default.
• W4207051048 cites W4226248453 @default.
• W4207051048 cites W4234285653 @default.
• W4207051048 cites W4242543569 @default.
• W4207051048 cites W4298017976 @default.
• W4207051048 cites W979396035 @default.
• W4207051048 doi "https://doi.org/10.1001/jama.2021.24110" @default.
• W4207051048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35076665" @default.
• W4207051048 hasPublicationYear "2022" @default.
• W4207051048 type Work @default.
• W4207051048 citedByCount "363" @default.
• W4207051048 countsByYear W42070510482021 @default.
• W4207051048 countsByYear W42070510482022 @default.
• W4207051048 countsByYear W42070510482023 @default.
• W4207051048 crossrefType "journal-article" @default.
• W4207051048 hasAuthorship W4207051048A5000498350 @default.
• W4207051048 hasAuthorship W4207051048A5005111256 @default.
• W4207051048 hasAuthorship W4207051048A5008298552 @default.
• W4207051048 hasAuthorship W4207051048A5014457694 @default.
• W4207051048 hasAuthorship W4207051048A5025817529 @default.
• W4207051048 hasAuthorship W4207051048A5033443383 @default.
• W4207051048 hasAuthorship W4207051048A5037780478 @default.
• W4207051048 hasAuthorship W4207051048A5040342415 @default.
• W4207051048 hasAuthorship W4207051048A5043667545 @default.
• W4207051048 hasAuthorship W4207051048A5045016557 @default.
• W4207051048 hasAuthorship W4207051048A5045519730 @default.
• W4207051048 hasAuthorship W4207051048A5046057748 @default.
• W4207051048 hasAuthorship W4207051048A5048412798 @default.
• W4207051048 hasAuthorship W4207051048A5051327428 @default.
• W4207051048 hasAuthorship W4207051048A5053157450 @default.
• W4207051048 hasAuthorship W4207051048A5053435953 @default.
• W4207051048 hasAuthorship W4207051048A5059550323 @default.
• W4207051048 hasAuthorship W4207051048A5067237537 @default.
• W4207051048 hasAuthorship W4207051048A5067425596 @default.
• W4207051048 hasAuthorship W4207051048A5068508825 @default.
• W4207051048 hasAuthorship W4207051048A5075918695 @default.
• W4207051048 hasAuthorship W4207051048A5077130040 @default.
• W4207051048 hasAuthorship W4207051048A5077383038 @default.
• W4207051048 hasAuthorship W4207051048A5081139573 @default.

• next